United States Drug Eluting Sinus Stent (DESS) Market Research Report 2022: Analysis by Procedures – Functional Endoscopic Sinus Surgery (FESS) and Balloon Sinus Dilation (BSD) – Forecast to 2025 – ResearchAndMarkets.com – Yahoo Finance

DUBLIN, March 24, 2022–(BUSINESS WIRE)–The "The US Drug Eluting Sinus Stent (DESS) Market: Analysis By Procedures (Functional Endoscopic Sinus Surgery (FESS) and Balloon Sinus Dilation (BSD)) Size & Trends with Impact of Covid-19 and Forecast up to 2025" report has been added to ResearchAndMarkets.com's offering.
The report provides an in depth analysis of the US drug eluting sinus stent (DESS) market by value. The report also provides a detailed analysis of the US sinus surgery market by sinusitis patients, chronic sinusitis patients, number of ENT eligible patients, number of procedures, etc.
The report also provides an analysis of the US Functional Endoscopic Sinus Surgery (FESS) and Balloon Sinus Dilation (BSD) market by Value and by number of procedures.
Sinusitis can be divided into Acute Sinusitis, Recurrent Acute Rhinosinusitis (RARS) and chronic Rhinosinusitis (CRS), on the basis of the duration of the episode of sinusitis and its severity. The treatment options for the sinusitis can be over-the-counter treatment, medical management and surgery.
The OTC treatment includes decongestants, antihistamines, pain relievers and nasal irrigation. Medical management includes antibiotics and oral and nasal steroids. The sinus surgeries are mainly of two types: Functional Endoscopic Sinus Surgery (FESS) and Balloon Sinus Dilation (BSD).
The US drug eluting sinus stent (DESS) market has increased significantly during the recent years, and projections are made that the market would rise in the next few years. The drug eluting sinus stent (DESS) market is expected to increase due to surging healthcare expenditure, increasing prevalence of sinus related disorders, growing treatment in physician's office, limitations of FESS, favorable government initiatives for promoting the use of sinus stents, etc. Yet the market faces some challenges such as economic slowdown, high cost involved, use of oral steroids and packing material, etc.
The report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the US drug eluting sinus stent (DESS) market has also been forecasted till the period 2025, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.
The US drug eluting sinus stent (DESS) market is concentrated with few major market players operating in the region.
The key players of the drug eluting sinus stent (DESS) market are Intersect ENT, Inc., Medtronic plc, Stryker Corporation (Entellus Medical, Inc.), and Johnson & Johnson (Acclarent, Inc.) are also profiled with their financial information and respective business strategies.
Key Topics Covered:
1. Executive Summary
2. Introduction
2.1 Sinus: An Overview
2.1.1 Types of Sinus
2.2 Sinusitis: An Overview
2.2.1 Types of Sinusitis
2.2.2 Treatment Options for Sinusitis
2.3 Drug Eluting Sinus Stent (DESS): An Overview
3. The US Market Analysis
3.1 The US Sinus Surgery Market: An Analysis
3.1.1 The US Sinus Surgery Market by Sinusitis Patients
3.1.2 The US Sinus Surgery Market by Chronic Sinusitis Patients
3.1.3 The US Sinus Surgery Market by Number of ENT Eligible Patients
3.1.4 The US Sinus Surgery Market by Surgical and Non Surgical ENT Eligible Patients
3.1.5 The US Sinus Surgery Market by Number of Procedures
3.1.6 The US Sinus Surgery Market Number of Procedures by Segments (Functional Endoscopic Sinus Surgery (FESS) and Balloon Sinus Dilation (BSD)
3.2 The US Functional Endoscopic Sinus Surgery (FESS) Market: An Analysis
3.2.1 The US Functional Endoscopic Sinus Surgery (FESS) Market by Value
3.2.2 The US Functional Endoscopic Sinus Surgery (FESS) Market by Number of Procedures
3.3 The US Balloon Sinus Dilation (BSD) Market: An Analysis
3.3.1 The US Balloon Sinus Dilation (BSD) Market by Value
3.3.2 The US Balloon Sinus Dilation (BSD) Market by Number of Procedures
3.3.3 The US Balloon Sinus Dilation (BSD) Market by Segments (operating room (OR) and Office)
3.3.4 The US Operating Room (OR) Balloon Sinus Dilation (BSD) Market by Value and by Number of Procedures
3.3.5 The US Office Balloon Sinus Dilation (BSD) Market by Value and by Number of Procedures
3.4 The US Drug Eluting Sinus Stent (DESS) Market: An Analysis
3.4.1 The US Drug Eluting Sinus Stent (DESS) Market by Value
4. Market Dynamics
4.1 Growth Driver
4.1.1 Surging Healthcare Expenditure
4.1.2 Increasing Prevalence of Sinus Related Disorders
4.1.3 Growing Treatment in Physician's Office
4.1.4 Limitations of FESS
4.1.5 Favorable Government Initiatives for Promoting the Use of Sinus Stents
4.2 Challenges
4.2.1 Economic Slowdown
4.2.2 High Cost Involved
4.2.3 Use of Oral Steroids and Packing Material
4.3 Market Trends
4.3.1 Introduction of Innovative Techniques in Sinus Surgery
4.3.2 Increasing Awareness among Patients towards the Chronic Sinusitis and Sinus Surgery
4.3.3 Rising Popularity of Minimally Invasive Surgeries
4.3.4 Shift from FESS to BSD
5. Competitive Landscape
5.1 The US Drug Eluting Sinus Stent (DESS) Market Players: A Financial Comparison
5.2 The US Drug Eluting Sinus Stent (DESS) Market Players by Products and Services
6. Company Profiles
6.1 Business Overview
6.2 Financial Overview
6.3 Business Strategy
Intersect ENT, Inc
Medtronic plc
Stryker Corporation (Entellus Medical, Inc.)
Johnson & Johnson (Acclarent, Inc.)
For more information about this report visit https://www.researchandmarkets.com/r/yc40g4
View source version on businesswire.com: https://www.businesswire.com/news/home/20220324005704/en/
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Yahoo Finance Live looks at several of the top cannabis companies as federal lawmakers discuss voting on legalization.
Shares of major marijuana stocks were rising on Friday after the House said it would consider a bill to decriminalize cannabis. But the enthusiasm may be unwarranted, analysts warn.
To be perfectly honest, few traders are revved up about AT&T stock, and for good reason. "The only redeeming quality of owning T has been the heady dividend yield," wrote Real Money Columnist Brad Ginesin recently. AT&T is set to split off Warner Bros to Discovery shareholders, which is likely to occur in mid-April.
Yahoo Finance Live's Emily McCormick examines Chinese stocks after Weibo gets added to a delisting watchlist.
A bill that would remove cannabis from the list of federally controlled substances will be voted on by Congressional lawmakers as early as next week, reports suggest.
Novavax Inc. said Friday that its experimental COVID-19 booster is being tested in a Phase 1/2 clinical trial sponsored by the National Institutes of Health. This study is evaluating Novavax's protein-based booster candidate in people who have already received the primary series of shots developed by BioNTech SE and Pfizer Inc. , Johnson & Johnson , or Moderna Inc. . (Novavax's COVID-19 vaccine has not been authorized in the U.S.; it is currently being reviewed by the Food and Drug Administratio
Every investor gets into the stock market to find the best returns. That’s been especially true for the past five years or so, as the Federal Reserve held interest rates at historic low levels. While the central bank has started reversing that policy, it will take time for rates to rise appreciably – and so for the near- to mid-term, stocks are likely to remain the best engine for finding returns-on-investment. The key to making the most out of a stock investment, however, is not just the return
These companies have the size for stability and the growth to produce significant gains for investors.
Bed Bath & Beyond moves quickly to get GameStop executive chairman Ryan Cohen off its back.
Nvidia CEO Jensen Huang talks to Yahoo Finance about the company's new Grace CPU and what it means for the chip giant's future.
NIO's (NIO) stock is trading slightly lower ahead of the Chinese electric-vehicle company's quarterly results due after the closing bell on Thursday.
Warren Buffett is undeniably the most closely watched, highest-profile investor in modern history. Not surprisingly, investors relentlessly clamor to match his success by analyzing his portfolio, hoping to absorb even a tiny morsel of Buffett's investment genius. Despite his unparalleled success, Buffett's investment model has always been transparent, straightforward, and consistent.
Artificial intelligence is integrated into so many products and services that we use every day that we hardly notice that it's there. The loan origination business is long overdue for disruption, and Upstart Holdings' (NASDAQ: UPST) AI-based platform is doing just that. The company's AI also makes applying for a loan ridiculously easy, with more than 70% of loans being fully automated.
Rivian Automotive has been in a decline since the middle of November but now we are seeing some green shoots on the charts and from the indicators. In this daily bar chart of RIVN, below, we can see that prices have declined to a low in mid-March.
These companies haven't said they'll split their stocks, but the topic should be on their minds.
German utilities on Thursday said their country needed an early warning system to tackle gas shortages, a day after Russia ordered the switch of contract payments to roubles, raising the risk of a supply squeeze and even higher prices. President Vladimir Putin's rouble payment demand, which IEA Executive Director Fatih Birol called a "security threat," added to market nervousness and called into question Russia's historic claim it is a reliable gas supplier regardless of geopolitics. Putin announced this demand on Wednesday, in the wake of the United States and European allies teaming up on a series of sanctions aimed at Russia after that nation's invasion Ukraine last month.
(Bloomberg) — Commodities markets have a well-worn saying that “the cure for high prices is high prices.” According to JPMorgan Chase & Co., the process may just be starting to happen in oil.Most Read from BloombergPutin Adviser Chubais Quits Over Ukraine War, Leaves RussiaChina Plane Crash Update: Search Continues for Second Black BoxRussia Central Banker Wanted Out Over Ukraine, Putin Said NoNATO Boosts Forces in East Amid Chemical Incidents WarningWall Street Is Scrambling For the Exits in M
Most people hear the phrase "technology stocks" these days and immediately think of volatile, rapid-growing investments suitable only for the boldest investors. There are several established tech stocks that not only grow but are also profitable and pay dividends to their shareholders, rewarding them for owning stock in the business. Here are three dividend-paying tech stocks that have industry-leading businesses in their respective specialties.
(Bloomberg) — Bausch Health Cos.’ plan to spin off a vision-care unit is a “fraudulent transfer” aimed at protecting valuable assets from securities litigation, a group of investors said.Most Read from BloombergChina Plane Crash Update: Search Continues for Second Black BoxPutin Adviser Chubais Quits Over Ukraine War, Leaves RussiaNATO Boosts Forces in East Amid Chemical Incidents WarningApple Is Working on a Hardware Subscription Service for iPhonesChina Crash Mystery Deepens as Evidence Sugge
You can buy pieces of some of the world's most exciting up-and-coming businesses for the price of a large pizza.

source

Leave a Comment

Your email address will not be published.

Shopping Cart